A CAR-T Win for Celgene (CELG) as Partner bluebird bio Releases 'Highly Promising' Results - Jefferies

December 1, 2016 7:57 AM EST
Get Alerts CELG Hot Sheet
Price: $112.31 -0.31%

Rating Summary:
    28 Buy, 8 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 24 | Down: 17 | New: 14
Trade CELG Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Jefferies analyst Brian Abrahams weighed in on Celgene (NASDAQ: CELG) after partner bluebird bio posted 'highly promising' bb2121 results in multiple myeloma.

Abrahams commented, "Data emerging from BLUE’s bb2121 (CELG-partnered) looks highly promising; though it will need to be replicated in a much broader pop., safety needs to stay clean, and durability and manufacturing/cost feasibility are unknowns with the approach, we believe it provides strong validation for CELG’s anti-BCMA candidates, helps offset recent BD/pipeline skepticism, and supports CELG’s underappreciated, multi-faceted MM life cycle extension strategy. "

The firm maintained a Buy rating and price target of $140 on BLUE.

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $118.51 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment